#USA #New York #Investor Conferences #Vanda Pharmaceuticals #VNDA

Vanda Pharmaceuticals to Participate in September 2025 Investor Conferences

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) has announced its participation in several prominent investor conferences slated for September 2025. This represents a significant opportunity for the company to engage with investors and share updates on its operations and upcoming products. Investors and stakeholders can look forward to detailed presentations that underscore Vanda's commitment to addressing major medical needs.

Conference Schedule

Vanda's participation will include three major events:

• - The Cantor Global Healthcare Conference 2025 in New York City, scheduled for September 3, 2025, at 3:55 p.m. Eastern Time.
• - The Wells Fargo Healthcare Conference 2025 in Boston, occurring on September 4, 2025, at 4:30 p.m. Eastern Time.
• - The H.C. Wainwright Annual Global Investment Conference, also in New York City, taking place on September 9, 2025, starting at 8:30 a.m. Eastern Time.

During each conference, Vanda executives will deliver corporate presentations aimed at informing attendees about the company’s recent innovations and strategic direction.

Accessing the Presentations

For those interested in tuning in, Vanda will provide live access to the presentations via its corporate website, www.vandapharma.com. Investors are encouraged to visit the site ahead of time to register and ensure they have any necessary software installed. After the live events, recordings will be available online for approximately 30 days, allowing broader access to those who are unable to attend live.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals has positioned itself as a leader in the biopharmaceutical landscape, focusing on the creation and commercialization of innovative therapies designed to meet significant unmet medical needs. The company's work remains centered around improving patient lives through groundbreaking treatments. For more information about Vanda and its initiatives, check out their website or follow them on social media platforms for the latest updates.

Through participation in these notable conferences, Vanda Pharmaceuticals is reinforcing its dedication to its investors and the medical community. Such engagements are crucial for fostering shareholder relationships and promoting transparency about the company's advancements and future projects.

Conclusion

As Vanda Pharmaceuticals prepares for September's investor conferences, the focus will be on communicating its latest innovations and strategic plans, ensuring stakeholders are well-informed about its trajectory. The presentations are expected to draw significant attention, emphasizing the company's role in the evolving biopharmaceutical sector and its ongoing commitment to enhancing patient care globally.